MCK vs. COR, CAH, BDX, ZTS, GILD, HCA, BMY, DXCM, EW, and GSK
Should you be buying McKesson stock or one of its competitors? The main competitors of McKesson include Cencora (COR), Cardinal Health (CAH), Becton, Dickinson and Company (BDX), Zoetis (ZTS), Gilead Sciences (GILD), HCA Healthcare (HCA), Bristol-Myers Squibb (BMY), DexCom (DXCM), Edwards Lifesciences (EW), and GSK (GSK). These companies are all part of the "medical" sector.
Cencora (NYSE:COR) and McKesson (NYSE:MCK) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, valuation, analyst recommendations, institutional ownership, media sentiment, community ranking, profitability, risk and earnings.
97.5% of Cencora shares are owned by institutional investors. Comparatively, 85.1% of McKesson shares are owned by institutional investors. 15.8% of Cencora shares are owned by company insiders. Comparatively, 0.2% of McKesson shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Cencora currently has a consensus price target of $233.90, suggesting a potential upside of 5.02%. McKesson has a consensus price target of $571.47, suggesting a potential upside of 3.07%. Given McKesson's higher probable upside, equities research analysts clearly believe Cencora is more favorable than McKesson.
In the previous week, McKesson had 48 more articles in the media than Cencora. MarketBeat recorded 55 mentions for McKesson and 7 mentions for Cencora. Cencora's average media sentiment score of 0.37 beat McKesson's score of 0.18 indicating that McKesson is being referred to more favorably in the news media.
McKesson has higher revenue and earnings than Cencora. Cencora is trading at a lower price-to-earnings ratio than McKesson, indicating that it is currently the more affordable of the two stocks.
Cencora has a beta of 0.47, indicating that its share price is 53% less volatile than the S&P 500. Comparatively, McKesson has a beta of 0.45, indicating that its share price is 55% less volatile than the S&P 500.
McKesson has a net margin of 0.97% compared to McKesson's net margin of 0.67%. McKesson's return on equity of 268.67% beat Cencora's return on equity.
Cencora pays an annual dividend of $2.04 per share and has a dividend yield of 0.9%. McKesson pays an annual dividend of $2.48 per share and has a dividend yield of 0.4%. Cencora pays out 22.3% of its earnings in the form of a dividend. McKesson pays out 11.1% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. Cencora has raised its dividend for 4 consecutive years and McKesson has raised its dividend for 16 consecutive years.
McKesson received 214 more outperform votes than Cencora when rated by MarketBeat users. Likewise, 74.16% of users gave McKesson an outperform vote while only 65.12% of users gave Cencora an outperform vote.
Summary
McKesson beats Cencora on 15 of the 21 factors compared between the two stocks.
Get McKesson News Delivered to You Automatically
Sign up to receive the latest news and ratings for MCK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MCK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
McKesson Competitors List
Related Companies and Tools
